The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results

Patrick D. Lyden, Francesca Bosetti, Márcio A. Diniz, André Rogatko, James I. Koenig, Jessica Lamb, Karisma A. Nagarkatti, Ryan P. Cabeen, David C. Hess, Pradip K. Kamat, Mohammad B. Khan, Kristofer Wood, Krishnan Dhandapani, Ali S. Arbab, Enrique C. Leira, Anil K. Chauhan, Nirav Dhanesha, Rakesh B. Patel, Mariia Kumskova, Daniel ThedensAndreia Morais, Takahiko Imai, Tao Qin, Cenk Ayata, Ligia S.B. Boisserand, Alison L. Herman, Hannah E. Beatty, Sofia E. Velazquez, Sebastian Diaz-Perez, Basavaraju G. Sanganahalli, Jelena M. Mihailovic, Fahmeed Hyder, Lauren H. Sansing, Raymond C. Koehler, Steven Lannon, Yanrong Shi, Senthilkumar S. Karuppagounder, Adnan Bibic, Kazi Akhter, Jaroslaw Aronowski, Louise D. McCullough, Anjali Chauhan, Andrew Goh

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Cerebral ischemia and reperfusion initiate cellular events in brain that lead to neurological disability. Investigating these cellular events provides ample targets for developing new treatments. Despite considerable work, no such therapy has translated into successful stroke treatment. Among other issues - such as incomplete mechanistic knowledge and faulty clinical trial design - a key contributor to prior translational failures may be insufficient scientific rigor during preclinical assessment: nonblinded outcome assessment; missing randomization; inappropriate sample sizes; and preclinical assessments in young male animals that ignore relevant biological variables, such as age, sex, and relevant comorbid diseases. Promising results are rarely replicated in multiple laboratories. We sought to address some of these issues with rigorous assessment of candidate treatments across 6 independent research laboratories. The Stroke Preclinical Assessment Network (SPAN) implements state-of-the-art experimental design to test the hypothesis that rigorous preclinical assessment can successfully reduce or eliminate common sources of bias in choosing treatments for evaluation in clinical studies. SPAN is a randomized, placebo-controlled, blinded, multilaboratory trial using a multi-arm multi-stage protocol to select one or more putative stroke treatments with an implied high likelihood of success in human clinical stroke trials. The first stage of SPAN implemented procedural standardization and experimental rigor. All participating research laboratories performed middle cerebral artery occlusion surgery adhering to a common protocol and rapidly enrolled 913 mice in the first of 4 planned stages with excellent protocol adherence, remarkable data completion and low rates of subject loss. SPAN stage 1 successfully implemented treatment masking, randomization, prerandomization inclusion/exclusion criteria, and blinded assessment to exclude bias. Our data suggest that a large, multilaboratory, preclinical assessment effort to reduce known sources of bias is feasible and practical. Subsequent SPAN stages will evaluate candidate treatments for potential success in future stroke clinical trials using aged animals and animals with comorbid conditions.

Original languageEnglish (US)
Pages (from-to)1802-1812
Number of pages11
Issue number5
StatePublished - May 1 2022


  • animals
  • cerebral arteries
  • clinical trial
  • research design
  • translational research

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing


Dive into the research topics of 'The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results'. Together they form a unique fingerprint.

Cite this